- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00662129
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Albumin-Bound Paclitaxel in Combination With Gemcitabine and Bevacizumab in Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving combination chemotherapy together with bevacizumab may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine together with bevacizumab works in treating patients with metastatic breast cancer.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
OBJECTIVES:
Primary
- To determine the 6-month progression-free survival rate of patients with metastatic breast cancer treated with paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and bevacizumab.
Secondary
- To determine the overall survival of patients treated with this regimen.
- To determine the progression-free survival of patients treated with this regimen.
- To determine the confirmed response rate in patients treated with this regimen.
- To determine the duration of response in patients treated with this regimen.
- To determine the time to treatment failure in patients treated with this regimen.
- To determine the quality of life of patients treated with this regimen.
OUTLINE: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and after every other course, and then after completion of treatment.
After completion of study treatment, patients are followed periodically for 5 years.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Arizona
-
Scottsdale, Arizona, Vereinigte Staaten, 85259-5499
- Mayo Clinic Scottsdale
-
-
Connecticut
-
Hartford, Connecticut, Vereinigte Staaten, 06105
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32224
- Mayo Clinic - Jacksonville
-
-
Indiana
-
Beech Grove, Indiana, Vereinigte Staaten, 46107
- St. Francis Hospital and Health Centers - Beech Grove Campus
-
Richmond, Indiana, Vereinigte Staaten, 47374
- Reid Hospital & Health Care Services
-
-
Iowa
-
Cedar Rapids, Iowa, Vereinigte Staaten, 52403
- Cedar Rapids Oncology Associates
-
Cedar Rapids, Iowa, Vereinigte Staaten, 52403
- Mercy Regional Cancer Center at Mercy Medical Center
-
Clive, Iowa, Vereinigte Staaten, 50325
- Medical Oncology and Hematology Associates - West Des Moines
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- CCOP - Iowa Oncology Research Association
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Vereinigte Staaten, 50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Mason City, Iowa, Vereinigte Staaten, 50401
- Mercy Cancer Center at Mercy Medical Center - North Iowa
-
Ottumwa, Iowa, Vereinigte Staaten, 52501
- McCreery Cancer Center at Ottumwa Regional
-
Sioux City, Iowa, Vereinigte Staaten, 51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City, Iowa, Vereinigte Staaten, 51104
- St. Luke's Regional Medical Center
-
Sioux City, Iowa, Vereinigte Staaten, 51104
- Mercy Medical Center - Sioux City
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor, Michigan, Vereinigte Staaten, 48106
- CCOP - Michigan Cancer Research Consortium
-
Battle Creek, Michigan, Vereinigte Staaten, 49017
- Battle Creek Health System Cancer Care Center
-
Big Rapids, Michigan, Vereinigte Staaten, 49307
- Mecosta County Medical Center
-
Dearborn, Michigan, Vereinigte Staaten, 48123-2500
- Oakwood Cancer Center at Oakwood Hospital and Medical Center
-
Flint, Michigan, Vereinigte Staaten, 48503
- Hurley Medical Center
-
Flint, Michigan, Vereinigte Staaten, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Butterworth Hospital at Spectrum Health
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- CCOP - Grand Rapids
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Lacks Cancer Center at Saint Mary's Health Care
-
Grosse Pointe Woods, Michigan, Vereinigte Staaten, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Jackson, Michigan, Vereinigte Staaten, 49201
- Foote Memorial Hospital
-
Lansing, Michigan, Vereinigte Staaten, 48912-1811
- Sparrow Regional Cancer Center
-
Livonia, Michigan, Vereinigte Staaten, 48154
- St. Mary Mercy Hospital
-
Muskegon, Michigan, Vereinigte Staaten, 49443
- Mercy General Health Partners
-
Pontiac, Michigan, Vereinigte Staaten, 48341-2985
- St. Joseph Mercy Oakland
-
Port Huron, Michigan, Vereinigte Staaten, 48060
- Mercy Regional Cancer Center at Mercy Hospital
-
Saginaw, Michigan, Vereinigte Staaten, 48601
- Seton Cancer Institute at Saint Mary's - Saginaw
-
Traverse City, Michigan, Vereinigte Staaten, 49684
- Munson Medical Center
-
Warren, Michigan, Vereinigte Staaten, 48093
- St. John Macomb Hospital
-
Wyoming, Michigan, Vereinigte Staaten, 49519
- Metro Health Hospital
-
-
Minnesota
-
Alexandria, Minnesota, Vereinigte Staaten, 56308
-
Burnsville, Minnesota, Vereinigte Staaten, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Vereinigte Staaten, 55433
- Mercy and Unity Cancer Center at Mercy Hospital
-
Duluth, Minnesota, Vereinigte Staaten, 55805
- CCOP - Duluth
-
Duluth, Minnesota, Vereinigte Staaten, 55805-1983
- Duluth Clinic Cancer Center - Duluth
-
Duluth, Minnesota, Vereinigte Staaten, 55805
- Miller - Dwan Medical Center
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Vereinigte Staaten, 55432
- Mercy and Unity Cancer Center at Unity Hospital
-
Hutchinson, Minnesota, Vereinigte Staaten, 55350
- Hutchinson Area Health Care
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Minnesota Oncology Hematology, PA - Maplewood
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- HealthEast Cancer Care at St. John's Hospital
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
-
Minneapolis, Minnesota, Vereinigte Staaten, 55415
- Hennepin County Medical Center - Minneapolis
-
Robbinsdale, Minnesota, Vereinigte Staaten, 55422-2900
- Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Mayo Clinic Cancer Center
-
Saint Cloud, Minnesota, Vereinigte Staaten, 56303
- CentraCare Clinic - River Campus
-
Saint Cloud, Minnesota, Vereinigte Staaten, 56303
- Coborn Cancer Center
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- CCOP - Metro-Minnesota
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- Park Nicollet Cancer Center
-
Saint Paul, Minnesota, Vereinigte Staaten, 55102
- United Hospital
-
Shakopee, Minnesota, Vereinigte Staaten, 55379
- St. Francis Cancer Center at St. Francis Medical Center
-
St. Paul, Minnesota, Vereinigte Staaten, 55101
- Regions Hospital Cancer Care Center
-
Waconia, Minnesota, Vereinigte Staaten, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Vereinigte Staaten, 56201
- Willmar Cancer Center at Rice Memorial Hospital
-
Woodbury, Minnesota, Vereinigte Staaten, 55125
- Minnesota Oncology Hematology, PA - Woodbury
-
-
Montana
-
Great Falls, Montana, Vereinigte Staaten, 59405-5309
- Big Sky Oncology
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Sletten Cancer Institute at Benefis Healthcare
-
-
Nebraska
-
Lincoln, Nebraska, Vereinigte Staaten, 68510
- Cancer Resource Center - Lincoln
-
Omaha, Nebraska, Vereinigte Staaten, 68106
- CCOP - Missouri Valley Cancer Consortium
-
Omaha, Nebraska, Vereinigte Staaten, 68122
- Immanuel Medical Center
-
Omaha, Nebraska, Vereinigte Staaten, 68124
- Alegant Health Cancer Center at Bergan Mercy Medical Center
-
Omaha, Nebraska, Vereinigte Staaten, 68131-2197
- Creighton University Medical Center
-
-
North Dakota
-
Bismarck, North Dakota, Vereinigte Staaten, 58501
- Bismarck Cancer Center
-
Bismarck, North Dakota, Vereinigte Staaten, 58501
- Medcenter One Hospital Cancer Care Center
-
Bismarck, North Dakota, Vereinigte Staaten, 58501
- Mid Dakota Clinic, PC
-
Bismarck, North Dakota, Vereinigte Staaten, 58502
- St. Alexius Medical Center Cancer Center
-
-
Ohio
-
Dayton, Ohio, Vereinigte Staaten, 45405
- Grandview Hospital
-
Dayton, Ohio, Vereinigte Staaten, 45406
- Good Samaritan Hospital
-
Dayton, Ohio, Vereinigte Staaten, 45409
- David L. Rike Cancer Center at Miami Valley Hospital
-
Dayton, Ohio, Vereinigte Staaten, 45415
- Samaritan North Cancer Care Center
-
Dayton, Ohio, Vereinigte Staaten, 45420
- CCOP - Dayton
-
Findlay, Ohio, Vereinigte Staaten, 45840
- Blanchard Valley Medical Associates
-
Franklin, Ohio, Vereinigte Staaten, 45005-1066
- Middletown Regional Hospital
-
Greenville, Ohio, Vereinigte Staaten, 45331
- Wayne Hospital
-
Kettering, Ohio, Vereinigte Staaten, 45429
- Charles F. Kettering Memorial Hospital
-
Troy, Ohio, Vereinigte Staaten, 45373-1300
- UVMC Cancer Care Center at Upper Valley Medical Center
-
Wilmington, Ohio, Vereinigte Staaten, 45177
- Clinton Memorial Hospital
-
Xenia, Ohio, Vereinigte Staaten, 45385
- Ruth G. McMillan Cancer Center at Greene Memorial Hospital
-
-
Oklahoma
-
Tulsa, Oklahoma, Vereinigte Staaten, 74136
- Natalie Warren Bryant Cancer Center at St. Francis Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18105
- Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57105
- Medical X-Ray Center, PC
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5039
- Sanford Cancer Center at Sanford USD Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed infiltrating breast cancer
- Clinical evidence of metastatic disease
Measurable disease, defined as at least one measurable lesion per RECIST criteria
No non-measurable disease only, defined as all other lesions, including small lesions (longest diameter < 2 cm) and truly non-measurable lesions, including any of the following:
- Bone lesions
- Leptomeningeal disease
- Ascites
- Pleural/pericardial effusion
- Inflammatory breast disease
- Lymphangitis cutis/pulmonis
- Abdominal masses that are not confirmed and followed by imaging techniques
- Cystic lesions
- Patients with HER-2/neu positive tumors, must have received prior treatment with trastuzumab (Herceptin®) or have a contraindication for trastuzumab
No evidence of active brain metastasis, including leptomeningeal involvement, on MRI or CT scan
CNS metastasis controlled by prior surgery and/or radiotherapy allowed
- Must be asymptomatic for ≥ 2 months with no evidence of progression prior to study entry
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- Life expectancy ≥ 12 weeks
- ECOG performance status 0-1
- ANC ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 9.0 g/dL
- AST and ALT ≤ 2.5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2.5 times ULN
- Total bilirubin ≤ 1.5 times ULN
- Creatinine ≤ 1.5 mg/dL
Urine protein:creatinine ratio < 1 or urinalysis < 1+ protein
- Patients discovered to have ≥ 1+ proteinuria at baseline must demonstrate 24-hour urine protein < 1 g
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 30 days after completion of study therapy
- Able to complete questionnaires alone or with assistance
- No peripheral neuropathy > grade 1
- No history of allergy or hypersensitivity to albumin-bound paclitaxel, paclitaxel, gemcitabine hydrochloride, bevacizumab, albumin, drug product excipients, or chemically similar agents
- No stage III or IV invasive, non-breast malignancy within the past 5 years
No other active malignancy, except nonmelanoma skin cancer or carcinoma in situ of the cervix
- Patient must not be receiving other specific treatment for a prior malignancy
No uncontrolled hypertension (i.e., blood pressure [BP] > 160/90 mm Hg on ≥ 2 occasions at least 5 minutes apart)
- Patients who have recently started or adjusted antihypertensive medications are eligible providing that BP is < 140/90 mm Hg on any new regimen for ≥ 3 different observations in ≥ 14 days
- No bleeding diathesis or uncontrolled coagulopathy
- No hemoptysis within the past 6 months
- No prior arterial or venous thrombosis within the past 12 months
- No history of cerebrovascular accident
- No history of hypertensive crisis or hypertensive encephalopathy
- No abdominal fistula or gastrointestinal perforation within the past 6 months
- No serious non-healing wound, ulcer, or fracture
No clinically significant cardiac disease, defined as any of the following:
- Congestive heart failure
- Symptomatic coronary artery disease
- Unstable angina
- Cardiac arrhythmias not well controlled with medication
- Myocardial infarction within the past 12 months
- No comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for study entry or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
No prior chemotherapy for metastatic disease
- May have received one prior adjuvant chemotherapy regimen
Prior neoadjuvant chemotherapy allowed
- More than 6 months since prior adjuvant or neoadjuvant taxane (i.e., docetaxel or paclitaxel) therapy
- Prior hormonal therapy in either adjuvant or metastatic setting allowed
More than 4 weeks since prior radiotherapy (except if to a non-target lesion only, or single dose radiation for palliation)
- Prior radiotherapy to a target lesion is allowed provided there has been clear progression of the lesion since radiotherapy was completed
- More than 4 weeks since prior cytotoxic chemotherapeutic agent or investigational drug
- More than 2 weeks since prior and no concurrent acetylsalicylic acid, anticoagulants, or thrombolytic agents (except for once-daily 81 mg acetylsalicylic acid)
- More than 6 weeks since prior major surgery, chemotherapy, or immunologic therapy
More than 1 week since prior minor surgery (e.g., core biopsy)
- Placement of a vascular access device within 7 days is allowed
- More than 3 months since prior neurosurgery
No concurrent treatment in a different clinical study in which investigational procedures are performed or investigational therapies are administered
- Trials related to symptom management (Cancer Control) which do not employ hormonal treatments or treatments that may block the path of the targeted agents used in this study may be allowed
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: paclitaxel + gemcitabine + bevacizumab
Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and after every other course, and then after completion of treatment. After completion of study treatment, patients are followed periodically for 5 years. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
6-month Progression-free Survival (PFS) Rate
Zeitfenster: at 6 months
|
The primary endpoint of this trial is the 6-month progression-free survival rate.
A patient is considered to be a 6-month progression-free survivor if the patient is 6 months from registration without a documentation of disease progression (note, the patient need not be on study treatment at 6 months to be considered a success).
The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients.
Confidence intervals for the true success proportion will be calculated using the properties of the binomial distribution.
Progression is defined using the RECIST Criteria, as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, appearance of one or more new lesions, or unequivocal progression of existing non-target lesions.
|
at 6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Overall Survival Time
Zeitfenster: Up to 5 years
|
Overall Survival time is defined as the time from registration to death due to any cause.
The distribution of survival time will be estimated using the method of Kaplan-Meier (1958).
|
Up to 5 years
|
PFS Time
Zeitfenster: Up to 5 years
|
Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression.
If a patient dies without a documentation of disease progression the patient will be considered to have had disease progression at the time of their death.
The distribution of time to progression will be estimated using the method of Kaplan-Meier (1958).
Progression is defined using the RECIST Criteria, as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, appearance of one or more new lesions, or unequivocal progression of existing non-target lesions.
|
Up to 5 years
|
Confirmed Response (Complete or Partial Response) Rate
Zeitfenster: Up to 5 years
|
A confirmed response is defined to be either a complete response (CR) or partial response (PR) noted as the objective status on 2 consecutive evaluations at least 8 weeks apart.
The confirmed response rate (percentage) will be estimated by the number of confirmed responses in evaluable patients divided by the total number of evaluable patients multiplied by 100.
The appropriate confidence interval will be calculated based on the binomial distribution.
|
Up to 5 years
|
Duration of Response
Zeitfenster: Up to 5 years
|
Duration of response is defined for all evaluable patients who have achieved a confirmed response as the date at which the patient's earliest best objective status is first noted to be either a CR or PR to the earliest date progression is documented.
If a patient dies subsequent to the confirmed response without a documentation of disease progression, the patient will be considered to have had disease progression at the time of their death.
In the case of a patient failing to return for evaluations before a documentation of disease progression, the patient will be censored for progression on the date of last evaluation.
The distribution of duration of response will be estimated using the method of Kaplan-Meier (1958).
|
Up to 5 years
|
Time to Treatment Failure
Zeitfenster: Up to 5 years
|
Time to treatment failure is defined to be the time from the date of registration to the date at which the patient is removed from treatment due to progression, adverse events, or refusal.
If the patient is considered to be a major treatment violation or is taken off study as a non-protocol failure, the patient will be censored on the date they were removed from treatment.
The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier (1958).
Progression is defined using the RECIST Criteria, as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, appearance of one or more new lesions, or unequivocal progression of existing non-target lesions.
|
Up to 5 years
|
Quality of Life, as Measure by the Mean Change in FACT-B TOI Score at Cycle 8
Zeitfenster: From baseline to end of Cycle 8; Up to 24 weeks
|
Quality of life (QOL) as measured by the mean change (from baseline) in FACT-B (TOI) Trial Outcome Index at Cycle 8 (24 weeks). FACT-B was scored according to the published scoring (*) criteria with higher scores representing better QOL. The FACT-B TOI was the sum of the following FACT-B subscale/scale scores: physical (score range 0-28), functional (score range 0-28), and Breast Cancer Subscale (score range 0-40); range of the FACT-B TOI is 0-96 (the change scores have a possible range of -96 to 96). The mean change and 95% confidence interval are reported below. A one-sample t-test is used to compare the change from baseline to a value of 0. (*)= Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast (FACT-B) quality of life instrument. J Clin Oncol 1997;15:974-986. |
From baseline to end of Cycle 8; Up to 24 weeks
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Studienstuhl: Donald W. Northfelt, MD, FACP, Mayo Clinic
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Northfelt DW, Dueck AC, Flynn TP, et al.: Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735. [Abstract] J Clin Oncol 29 (Suppl 15): A-1126, 2011.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Hautkrankheiten
- Neubildungen
- Neubildungen nach Standort
- Brusterkrankungen
- Neoplasien der Brust
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Enzym-Inhibitoren
- Antimetaboliten, antineoplastisch
- Antimetaboliten
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Tubulin-Modulatoren
- Antimitotische Mittel
- Mitose-Modulatoren
- Antineoplastische Mittel, Phytogen
- Antineoplastische Mittel, immunologische
- Angiogenese-Inhibitoren
- Angiogenese-modulierende Mittel
- Wuchsstoffe
- Wachstumshemmer
- Gemcitabin
- Paclitaxel
- Bevacizumab
- Albumingebundenes Paclitaxel
Andere Studien-ID-Nummern
- NCCTG-N0735
- NCI-2009-00666 (Registrierungskennung: CTRP (Clinical Trials Reporting System))
- CDR0000593581 (Registrierungskennung: PDQ (Physician Data Query))
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Brustkrebs
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
Klinische Studien zur Gemcitabinhydrochlorid
-
Hunan Province Tumor HospitalRekrutierungKarzinom, nicht-kleinzellige Lunge | EGFR-GenmutationChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Rekrutierung
-
AkesoAkeso Tiancheng, IncAbgeschlossenNasopharynxkarzinomChina
-
Albert Einstein College of MedicineShanghai Proton and Heavy Ion CenterAbgeschlossenKrebs | BauchspeicheldrüsenkrebsVereinigte Staaten, China
-
Spanish Cooperative Group for the Treatment of...Hoffmann-La RocheAbgeschlossenMetastasierter BauchspeicheldrüsenkrebsSpanien
-
Samsung Medical CenterAbgeschlossenNicht resezierbares, metastasiertes Karzinom der GallenwegeKorea, Republik von
-
NovaceaSchering-PloughSuspendiertBauchspeicheldrüsenkrebsVereinigte Staaten
-
Centro Nacional de Investigaciones Oncologicas...Apices Soluciones S.L.; Hospital Universitario de Fuenlabrada; Grupo Hospital...AbgeschlossenFortgeschrittenes PankreaskarzinomSpanien
-
Zhejiang Cancer HospitalUnbekannt
-
Gyeongsang National University HospitalChung-Ang University Hosptial, Chung-Ang University College of Medicine; Dong-A...AbgeschlossenMetastasierter BauchspeicheldrüsenkrebsKorea, Republik von